Retatrutide vs Semaglutide

Nearly double the weight loss. Almost opposite side effect profiles. A side-by-side comparison using 8,664 real patient posts from Reddit and published clinical trial data. Not medical advice — evidence to inform your conversation with your doctor.

3,580
Retatrutide Posts
5,084
Semaglutide Posts
222
Switched Sema → Reta

Weight Loss Efficacy

Clinical trial results at the highest studied doses. No head-to-head trial exists — these are cross-trial comparisons.

28.7%
−71.2 lbs average
TRIUMPH-4 Phase 3 (12mg, 68 weeks)
n=445, obesity + knee OA
vs
14.9%
−34.6 lbs average
STEP 1 Phase 3 (2.4mg, 68 weeks)
n=1,961 (1,306 semaglutide arm)
Important Context

The weight loss gap here is the largest between any two GLP-1 drugs. But these were different trials with different populations — TRIUMPH-4 enrolled patients with obesity plus knee osteoarthritis (mean BMI 40.4), while STEP 1 enrolled general obesity (mean BMI 37.9). Retatrutide’s triple-agonist mechanism (GLP-1 + GIP + glucagon) provides fundamentally more metabolic activity than semaglutide’s single GLP-1 action. This is the biggest mechanistic difference between any two drugs in the GLP-1 class.

Side Effects Comparison

Percentage of Reddit posts for each drug mentioning each side effect, with raw post counts shown. Based on 3,580 retatrutide and 5,084 semaglutide posts.

Side EffectRetatrutideSemaglutideSignal
Nausea 14.2%509 posts 21.2%1,076 posts1.6× Sema-Elevated
Semaglutide has the highest nausea rate of all three GLP-1 drugs. 1,076 posts — the single largest side effect signal in the entire dataset.
Fatigue 12.6%450 posts 9.8%497 posts Similar rates. Sema fatigue (9.8%) near-perfectly matches the Wegovy FDA label (11%).
Heart Rate Increase 7.2%257 posts4.2× 1.8%91 posts Reta-Specific
Appears at first injection, not dose-dependent. Likely binary — you either get it or you don’t.
Insomnia 6.4%230 posts3.4× 2.1%105 posts Reta-Specific
4.5× more common in first 4 weeks. Usually self-resolving. Morning injections help.
Diarrhea 5.9%210 posts 6.6%335 posts Sema modestly higher.
Constipation 3.7%132 posts 6.3%322 posts2.2× Sema-Elevated
322 posts. Semaglutide has the highest constipation rate across all three drugs.
Skin Sensitivity 5.6%199 posts6.1× 1.1%55 posts Reta-Specific
Dose-dependent: 3% at 1mg → 25% at 12mg. Confirmed by Phase 3 at 20.9%.
Acid Reflux 3.9%140 posts 4.5%229 posts Sema slightly elevated.
Vomiting 0.9%31 posts 3.0%150 posts3.3× Sema-Elevated
Both drugs massively underreported vs trials (sema trial: 24.8%).
Hair Loss 1.3%47 posts 3.1%159 posts Sema 2× reta. Telogen effluvium from rapid weight loss, months 3–6.
Low Libido 1.5%54 posts3.3× 0.6%28 posts Reta-Specific
Not measured in any clinical trial. Reddit-only data point.
Key Takeaway

These drugs have almost opposite side effect profiles. Semaglutide dominates in GI side effects — nausea (1,076 posts, 1.5× reta), constipation (322 posts, 1.7×), and vomiting (150 posts, 3.4×). Retatrutide dominates in non-GI side effects — heart rate (257 posts, 4.0×), insomnia (230 posts, 3.1×), skin sensitivity (199 posts, 5.1×), and low libido (54 posts, 2.7×). If you’re sensitive to GI issues, retatrutide may be more tolerable. If you’re sensitive to sleep or cardiovascular disruption, semaglutide may be easier.

Clinical Trials vs Real-World Data

Published trial results compared to what 8,664 Reddit users reported. Arrows show whether Reddit under- or over-counts relative to trials.

Side EffectReta TrialReta RedditSema TrialSema RedditPattern
Nausea43%14.2%50943.9%21.2%1076↓ Undercounted
Vomiting21%0.9%3124.8%3.0%150↓↓ Heavily under
Diarrhea15%5.9%21029.7%6.6%335↓ Undercounted
Constipation12%3.7%13224.2%6.3%322↓ Undercounted
Skin Sensitivity20.9%5.6%199N/A1.1%55↓ Undercounted
Fatigue7–10%12.6%45011%9.8%497→ Sema aligned
InsomniaNot captured6.4%230Not captured2.1%105★ New signal
Low LibidoNot measured1.5%54Not measured0.6%28★ New signal
Why The Numbers Differ

Reddit systematically undercounts acute GI symptoms (nausea, vomiting, diarrhea) because people don’t open Reddit mid-episode. Semaglutide’s fatigue rate is the single best Reddit-to-trial alignment in the dataset — 9.8% vs the Wegovy label’s 11%. This gives us confidence that when Reddit and trial data measure the same quality-of-life effect, they converge. The signals Reddit captures that trials don’t — insomnia, low libido, craving reduction — are genuinely new information.

What Clinical Trials Missed

Side effects and patterns invisible to clinical research by design.

Not in any trial
54 posts
Low Libido Absent From Trials
Not asked in trial questionnaires for either drug. 54 retatrutide users reported it vs 28 semaglutide users — completely invisible to clinical research.
Not captured as adverse event
230 posts
Insomnia Not in Trial Data
230 retatrutide users posted about insomnia vs 105 semaglutide users. Neither trial program captured this. 4.5× more common in first 4 weeks on reta, usually self-resolving.
Not measured in obesity trials
4.0% across all drugs
Addiction & Craving Reduction
Reduced alcohol cravings, gambling urges, and addictive behaviors reported uniformly across reta and sema. Obesity trials don’t measure this — one of the most significant real-world findings.
Reddit dramatically undercounts
Sema: 4.0% vs 24.8% trial
Vomiting Gap Is 6×
Semaglutide vomiting on Reddit (4.0%) vs STEP trials (24.8%) is the largest single gap in the dataset. People don’t post about acute episodes — they post about chronic quality-of-life problems.
Methodology Validation

When Reddit data and clinical trials measure the same thing, the numbers converge. Semaglutide fatigue on Reddit (9.8%) near-perfectly matches the Wegovy FDA label (11%). Retatrutide skin sensitivity on Reddit (5.6%) aligned with Phase 2 trial data (7%), and Phase 3 TRIUMPH-4 later confirmed the dose-dependent pattern at 20.9% at 12mg. This overlap gives us confidence in the signals Reddit captures that trials don’t measure.

Severity Profile

Of all side effect reports, what percentage were rated mild, moderate, or severe.

Retatrutide (3,097 reports)
Mild
37%
Moderate
40%
Severe
20%
Semaglutide (4,144 reports)
Mild
27%
Moderate
42%
Severe
30%
What This Means

Semaglutide has the worst severity profile of all three GLP-1 drugs — 30% of 4,144 reports rated severe, vs just 22% for retatrutide. Semaglutide also has the lowest mild rate (27% vs 37%). This likely reflects semaglutide’s intense GI burden: nausea and vomiting are inherently more disabling than retatrutide’s characteristic side effects (insomnia, skin sensitivity), which are uncomfortable but less acutely debilitating.

Benefits Comparison

Positive effects reported beyond weight loss, with raw post counts. Benefits are underreported — people post about problems more than wins.

BenefitRetatrutideSemaglutideSignal
Food Noise Eliminated 23.8%853 posts 17.3%879 posts Sema has more raw mentions (879 vs 853) due to larger user base. Reta has higher rate per user. Both strongly reported.
Energy Increased 10.0%357 posts 5.0%253 posts Reta Leads
Reta users report energy gains at 2.0× the rate of sema users.
Blood Pressure Normalized 2.5%90 posts 4.9%250 posts Sema leads. TRIUMPH-4 showed −14mmHg systolic on reta 12mg.
Inflammation Reduced 4.2%152 posts 2.8%141 posts Similar raw counts. Reta has higher rate per user.
Mental Clarity 3.9%139 posts 3.1%158 posts Similar rates in the updated dataset.
Reduced Alcohol Cravings 3.9%139 posts 2.9%148 posts Uniform across all drugs — mechanism-level GLP-1 effect on nucleus accumbens.
Key Takeaway

Retatrutide has the stronger benefit profile per user across food noise (23.8% vs 17.3%) and energy (10.0% vs 5.0%). Semaglutide leads in blood pressure normalization (4.9% vs 2.5%). Both drugs show similar rates for inflammation, mental clarity, and alcohol craving reduction. Retatrutide’s additional GIP and glucagon activity appears to provide more aggressive appetite suppression, while semaglutide’s benefit profile is more balanced.

Semaglutide’s Unique Advantage: Cardiovascular Risk Reduction

The SELECT trial (n=17,604) showed semaglutide reduced major adverse cardiovascular events by 20% in people with existing cardiovascular disease but without diabetes. No other GLP-1 drug has this evidence. This is not captured in the Reddit benefit data above, but it’s the single strongest clinical argument for semaglutide — particularly for patients with a history of heart disease. Retatrutide has no cardiovascular outcomes data yet.

Switching Between Drugs

What happens when people switch — and why the flow is overwhelmingly one-directional.

Semaglutide → Retatrutide
222 people
Why: Inadequate weight loss on semaglutide, wanting more aggressive results. 11.7% of all drug switches in the dataset. Many switched after plateauing on 2.4mg.
Retatrutide → Semaglutide
12 people
Why: Cost concerns, returning to a known tolerable and FDA-approved agent. Just 0.6% of all switches — the least common route in the entire dataset. Likely undercounted — these users post in r/Ozempic and r/Semaglutide, not reta communities.
What This Tells Us

The switch ratio is 18:1 in favor of sema→reta. Nobody switches back. This is even more one-directional than the tirz→reta flow (306 switches, 8.5:1 ratio). The most common pattern is sema→tirz (535 people) and then tirz→reta (565 people) — a clear escalation path through the GLP-1 class as people seek stronger results. For a detailed look at what the sema-to-reta transition actually looks like, see our switching to retatrutide analysis.

Who Might Prefer Each Drug

Based on the data — not a recommendation. Always discuss with your healthcare provider.

Consider Retatrutide If…

  • You’ve plateaued on semaglutide and want significantly more aggressive weight loss
  • GI side effects (nausea, constipation, vomiting) are your main concern — reta has a milder GI profile
  • You want broader metabolic benefits beyond weight loss (energy, blood pressure, mental clarity)
  • You’re comfortable with a not-yet-approved, compounded medication
  • You can tolerate potential sleep disruption and heart rate changes in the first few weeks

Consider Semaglutide If…

  • You want an FDA-approved medication with established insurance coverage (Wegovy/Ozempic)
  • You’re sensitive to sleep disruption, cardiovascular effects, or skin sensitivity
  • You prefer the largest long-term safety dataset of any GLP-1 drug (STEP program + 6 years post-market)
  • You want proven cardiovascular risk reduction (SELECT trial: 20% reduction in MACE events)
  • You’re starting your first GLP-1 and want the most studied option available

Frequently Asked Questions

Is retatrutide better than semaglutide for weight loss?
In clinical trials, retatrutide produced nearly double the weight loss — 28.7% at 68 weeks (TRIUMPH-4) vs 14.9% at 68 weeks (STEP 1). This is the largest weight loss gap between any two GLP-1 drugs. Retatrutide’s triple-agonist mechanism (GLP-1 + GIP + glucagon) provides additional metabolic pathways that semaglutide’s single GLP-1 action doesn’t have. However, these were different trials, and retatrutide is not yet FDA approved.
Can you switch from semaglutide to retatrutide?
Yes — 222 people in our dataset made this switch, accounting for 11.7% of all drug switches we observed. The primary reason was inadequate weight loss on semaglutide. Most people reported restarting titration from a low dose. Interestingly, many people go sema→tirz first (365 switches) and then tirz→reta (306 switches) rather than jumping directly. Discuss any switch with your healthcare provider. For a deep dive into what actually happens after switching, see our analysis of 256 switching posts — including sema-specific dose conversion tables and the transition timeline.
What side effects does retatrutide have that semaglutide doesn’t?
Retatrutide has three distinct signals that are largely absent from semaglutide: heart rate increase (7.2% vs 1.8%, based on 257 vs 91 posts), insomnia (6.4% vs 2.1%, 230 vs 105 posts), and skin sensitivity (5.6% vs 1.1%, 199 vs 55 posts). It also shows elevated low libido (1.5% vs 0.6%, 54 vs 28 posts). These appear related to retatrutide’s additional glucagon receptor activity. In the other direction, semaglutide has much worse nausea (21.2% vs 14.2%), constipation (6.3% vs 3.7%), and vomiting (3.0% vs 0.9%).
Is retatrutide FDA approved?
No. As of March 2026, retatrutide is not FDA approved. It is in Phase 3 clinical trials (TRIUMPH program, 5,800+ participants). Seven trials are expected to report in 2026. FDA approval is not expected before late 2027. Retatrutide is currently only available through compounding pharmacies or clinical trials. Semaglutide is FDA approved as Wegovy (weight loss) and Ozempic (type 2 diabetes) and has been on the market since 2021.
Which drug has fewer side effects overall?
Semaglutide has the worst severity profile of all three GLP-1 drugs — 29% of 3,629 reports rated severe vs 20% of 2,431 for retatrutide. However, retatrutide has more unique side effects (heart rate, insomnia, skin sensitivity, low libido) that semaglutide users rarely experience. The drugs burden different systems: semaglutide hits the gut harder, retatrutide affects sleep, heart rate, and skin. Neither is strictly “safer” — it depends on your personal sensitivity profile.
Is semaglutide safer than retatrutide?
Semaglutide has a much longer safety track record — FDA approved since 2021, with the STEP program (n=4,500+) and the SELECT cardiovascular outcomes trial (n=17,604) providing years of post-market data. Retatrutide is still in Phase 3 trials and has no long-term safety data beyond 68 weeks. On the other hand, our real-world data shows semaglutide has a higher severe side effect rate (29% vs 20%) and more intense GI burden. “Safer” depends on whether you’re asking about known risk profile (semaglutide wins) or day-to-day tolerability (retatrutide may be easier for many people). Always consult your healthcare provider.

Explore the full dataset

Search all 14,252 posts across retatrutide, tirzepatide, and semaglutide.

Search the Data →

📄 Download the Full Report (PDF)

22-page analysis — side effects, remedies, benefits, women’s health, clinical trial comparisons, and recommendations by drug.

Download Free →

Other Comparisons

Compare
Retatrutide vs Tirzepatide
View comparison →
Compare
Tirzepatide vs Semaglutide
View comparison →
This analysis combines self-reported Reddit data with published clinical trial results. It is not medical advice. Full methodology →
Clinical Trial Sources
Eli Lilly. “TRIUMPH-4 Phase 3 Results.” Press release, December 11, 2025. n=445, 68 weeks. NCT05931367. Source
Jastreboff AM, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity.” N Engl J Med. 2023;389:514-526. Phase 2, n=338. DOI
Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” N Engl J Med. 2021;384:989-1002. STEP 1, n=1,961. DOI
Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” N Engl J Med. 2023;389:2221-2232. SELECT trial, n=17,604. DOI
Reddit data: n=8,664 posts (3,580 retatrutide + 5,084 semaglutide) from 6 subreddits, analyzed March 2026 via Claude Sonnet 4.6.